

Monthly Portfolio Update

Pioneer Funds – U.S. Fundamental Growth

31 May 2017

EQUITY

COMMENTARY

Market Review

U.S. equity markets posted their seventh consecutive month of positive returns, with the S&P 500 Index returning 1.4% for the month of May. Growth stocks once again outperformed value stocks in the month as near-term optimism regarding an acceleration in economic growth due to public policy changes continued to fade and investors rewarded stocks with secular, rather than cyclical growth. The Russell 1000 Growth Index returned 2.6% vs. -0.1% for the Russell 1000 Value Index.

Nine of the eleven sectors in the growth index posted positive results for the month, led by Information Technology (+5.4%) and Utilities (+5.3%). Energy (-6.2%) and Healthcare (-0.1%) were the worst performing sectors.

Portfolio Review

The Portfolio underperformed the 2.6% return of the Russell 1000 Growth Index. The Portfolio's underperformance for the month was due to both sector allocation and stock selection. While the Portfolio has less than 2% invested in Energy stocks, this allocation is higher than the benchmark weighting of 0.5% and was thus a drag on performance. The overweight in the underperforming Healthcare sector also slightly detracted from performance, as did a modest underweight in the Information Technology sector.

Individual detractors included Celgene, a biotechnology company. The stock declined after releasing modestly disappointing results in a clinical trial for a drug in development for multiple sclerosis. However, we believe that the product pipeline overall remains strong and that the stock is attractively valued given its growth prospects. Allergan, a pharmaceutical company, fell

despite posting solid first quarter results due to the lack of near-term product pipeline catalysts to move the stock higher and general concern related to pricing in the Healthcare sector. We believe Allergan's exposure to consumer-oriented products, such as Botox, will enable it to perform well even if pricing pressures for drugs that are paid for by third parties increases. CVS Health, a retail pharmacy chain and pharmacy benefit manager, declined due to continued concerns regarding pricing pressure for pharmaceutical products. While we are monitoring the pricing environment, we believe the company will be able to generate profitable growth over time.

Individual contributors to performance included Alphabet, the leading search engine company, it rose due to continued growth in online search and cloud computing. Cognizant Technologies, a provider of technology consulting and outsourcing services, increased due to strong quarterly earnings. MasterCard, a leading global payments company, rose due to better-than-expected quarterly earnings and a positive outlook.

Trading Activity

We added one new holding and removed one holding in the month of May. We added Cooper Companies, one of the leading global manufacturers of contact lenses with a particularly strong market position in specialty lenses such as multifocal lenses. The contact lens industry has attractive secular growth potential and the competitive environment is stable. We believe that Cooper's recent investments in product development and manufacturing capacity are likely to generate growth and attractive returns on capital while the stock trades at an attractive valuation.

We sold Kimberly Clark due to increased competition within the personal care industry. Industry growth rates have slowed so competitors have increased promotions

and have been more aggressive with pricing in an effort to take market share. Kimberly Clark has strong brands and is an efficiently run company but the increased competitive intensity may result in lower growth and lower returns on growth capital.

Outlook

Despite a recovery in earnings growth, we are cautious in our outlook for equities given high valuations. Though tax cuts and other pro-growth government policies may further boost growth, there are significant factors that could undermine growth including the potential for the Fed to raise interest rates more aggressively if inflation increases, possible negative repercussions from restrictive immigration and trade policies, and geopolitical issues.

The Portfolio remains conservatively positioned with an overweight in Consumer Staples stocks, which traditionally have outperformed when equity markets have declined due to the stability of their businesses. In addition, we are overweight the Healthcare sector as we believe a major change to the way drugs are priced is unlikely and the sector is trading at the lower end of its historic range relative to the overall market. While growth stocks have performed well this year, much of the performance has been driven by a small set of highly valued growth stocks, which we believe could be vulnerable when the market corrects. Volatility has been exceptionally low over the last few months but this may change if inflationary pressure continues to build leading to further tightening of monetary policy.

Important Information

Unless otherwise stated all information contained in this document is from Pioneer Investments and is as at 31 May 2017.

Pioneer Funds – U.S. Fundamental Growth is a sub-fund (the “Sub-Fund”) of Pioneer Funds (the “Fund”), a fonds commun de placement with several separate sub-funds established under the laws of the Grand Duchy of Luxembourg.

The Sub-Fund is actively managed, and current holdings may be different. References to individual stocks should not be taken as an investment recommendation to buy or sell any particular stock.

Past performance does not guarantee and is not indicative of future results. Unless otherwise stated, all views expressed are those of Pioneer Investments. These views are subject to change at any time based on market and other conditions and there can be no assurances that countries, markets or sectors will perform as expected. Investments involve certain risks,

including political and currency risks. Investment return and principal value may go down as well as up and could result in the loss of all capital invested. More recent returns may be different than those shown. Please contact your local Pioneer Investments representative for more current performance results.

This material is not a prospectus and does not constitute an offer to buy or a solicitation to sell any units of the Fund or any services, by or to anyone in any jurisdiction in which such offer or solicitation would be unlawful or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation. For additional information on the Fund, a free prospectus should be requested from Pioneer Global Investments Limited (“PGIL”), 1 George’s Quay Plaza, George’s Quay, Dublin 2, Ireland. Call +353 1 480 2000 Fax +353 1 449 5000 or your local Pioneer Investments sales office.

This information is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities or services in the United States or in any of its territories or possessions subject to its jurisdiction or for the benefit of any Restricted U.S. Investor (as defined in the prospectus of the Fund). The Fund has not been registered in the United States under the Investment Company Act of 1940 and units of the Fund are not registered in the United States under the Securities Act of 1933. This document is not intended for and no reliance can be placed on this document by retail clients, to whom the document should not be provided.

The content of this document is approved by Pioneer Global Investments Limited. In the UK, it is directed at professional clients and not at retail clients and it is approved for distribution by Pioneer Global Investments Limited (London Branch), Portland House, 8th Floor, Bressenden Place, London SW1E 5BH. Pioneer Global Investments Limited is authorised and regulated by the Central Bank of Ireland and subject to limited regulation by the Financial Conduct Authority. Details about the extent of our regulation by the Financial Conduct Authority (“FCA”) are available from us on request. The Fund is an unregulated collective investment scheme under the UK Financial Services and Markets Act 2000 and therefore does not carry the protection provided by the UK regulatory system.

Pioneer Funds Distributor, Inc., 60 State Street, Boston, MA 02109 (“PFD”), a U.S.-registered broker-dealer, provides marketing services in connection with the distribution of Pioneer Investments’ products. PFD markets these products to financial intermediaries, both within and outside of the U.S. (in jurisdictions where permitted to do so) for sale to clients who are not United States persons.

For Broker/Dealer Use Only and not to be Distributed to the Public.

Pioneer Investments is a trading name of the Pioneer Global Asset Management S.p.A. group of companies.

Date of First Use: 14 June 2017

Doc ID: 184771